coronary artery disease - anti-anginal drugs - all type of patients clinical trials results meta-analysis

<h1> <a href="TM29-88-anti-anginaldrugs-coronaryarterydisease.html"> <strong>coronary artery disease</strong> - anti-anginal drugs </a> - all type of patients trial results systematic overview and meta-analysis </h1> <h2>Main characteristics of the included studies</h2> <table> <tr> <th>Trial</th> <th>Treatments</th> <th>Patients</th> <th>Methods</th> </tr> <tr> <td> <a href="TRC_t5739.html"> ERICA, 2006 </a> <br> NCT00091429 </td> <td> ranolazine 1000 mg twice a day for 6 weeks + amlodipine (10 mg/d)<br>  <i>versus</i> <br> placebo + amlodipine (10 mg/d) </td> <td> patients with stable chronic angina already treated with the maximal dose of amlodipine (10mg/d) </td> <td> follow-up 6 weeks<br> n=281/284<br> Parallel groups<br> double blind <br> Europe, USA, Canada </td> </tr> <tr> <td> <a href="index.html"> MARIZA, 2004 </a> <br> </td> <td> ranolazine 500 mg twice daily (sustained-release ranolazine 500, 1,000, or 1,500 mg)<br>  <i>versus</i> <br> placebo </td> <td> Patients with angina-limited exercise </td> <td> follow-up 1 week<br> n=191/191<br> Cross over<br> double blind <br> US, Czech Republic, Poland, Canada </td> </tr> <tr> <td> <a href="index.html"> RAN080, 2005 </a> <br> </td> <td> ranolazine IR 400mg TID<br>  <i>versus</i> <br> placebo </td> <td> patients who had symptom-limited exercise </td> <td> follow-up 1 week<br> n=158/158<br> Cross over<br> double blind <br> Europe, canada </td> </tr> <tr> <td> <a href="index.html"> CARISA 1000mg, 2004 </a> <br> </td> <td> ranozaline 1000mg (in combination with beta-blockers or calcium antagonists)<br>  <i>versus</i> <br> placebo </td> <td> patients with severe chronic angina who have symptoms of chronic angina and who experience angina and ischemia at low workloads despite taking standard doses of atenolol, amlodipine, or diltiazem </td> <td> follow-up 12 weeks<br> n=261/258<br> Parallel groups<br> double blind <br> </td> </tr> </table> <h2>References</h2> <p> <b>ERICA, 2006 : </b> Stone PH, Gratsiansky NA, Blokhin A, Huang IZ, Meng LAntianginal efficacy of ranolazine when added to treatment with amlodipine: the ERICA (Efficacy of Ranolazine in Chronic Angina) trial. <i>J Am Coll Cardiol 2006 Aug 1;48:566-75</i> [PMID 16875985] </p> <p> <b>CARISA 750mg, 2004 : </b> Chaitman BR, Pepine CJ, Parker JO, Skopal J, Chumakova G, Kuch J, Wang W, Skettino SL, Wolff AAEffects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: a randomized controlled trial. <i>JAMA 2004 Jan 21;291:309-16</i> [PMID 14734593] </p> <p> <b>MARIZA, 2004 : </b> Chaitman BR, Skettino SL, Parker JO, Hanley P, Meluzin J, Kuch J, Pepine CJ, Wang W, Nelson JJ, Hebert DA, Wolff AAAnti-ischemic effects and long-term survival during ranolazine monotherapy in patients with chronic severe angina. <i>J Am Coll Cardiol 2004;43:1375-82</i> [PMID 15093870] </p> <p> <b>RAN080, 2005 : </b> Rousseau MF, Pouleur H, Cocco G, Wolff AAComparative efficacy of ranolazine versus atenolol for chronic angina pectoris. <i>Am J Cardiol 2005;95:311-6</i> [PMID 15670536] </p> <p> <b>CARISA 1000mg, 2004 : </b> Chaitman BR, Pepine CJ, Parker JO, Skopal J, Chumakova G, Kuch J, Wang W, Skettino SL, Wolff AAEffects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: a randomized controlled trial. <i>JAMA 2004 Jan 21;291:309-16</i> [PMID 14734593] </p> <p> <b>Meyer, 1993 : </b> Meyer BJ, Amann FWAdditional antianginal efficacy of amiodarone in patients with limiting angina pectoris. <i>Am Heart J 1993;125:996-1001</i> [PMID 8465772] </p> <p> <b>varin, 1990 : </b> Varin J, Pelissier C, Legendre M, Delorme G, Dubourg O, Weiss P, Bourdarias JP[Anti-angina effect of amiodarone versus delayed-action propranolol. A double-blind randomized study] <i>Arch Mal Coeur Vaiss 1990 Aug;83:1467-73</i> [PMID 2122869] </p> <p> <b>Pepine, 1999 : </b> Pepine CJ, Wolff AA, A controlled trial with a novel anti-ischemic agent, ranolazine, in chronic stable angina pectoris that is responsive to conventional antianginal agents. Ranolazine Study Group. <i>Am J Cardiol 1999;84:46-50.</i> [PMID 10404850] </p>